Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline

View original at globenewswire.com
Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Dynavax acquisition agreement should not affect Sanofi's financial outlook for 2025

    80% confidence

  • Dynavax strengthens Sanofi's presence in adult vaccination by bringing differentiated vaccines that complement Sanofi's expertise

    80% confidence

  • This transaction and the attractive value it brings serves the best interests of the Company and its shareholders

    80% confidence

  • Joining Sanofi will bring the global scale and expertise needed to maximize the impact of Dynavax's vaccine portfolio

    80% confidence

  • The acquisition is expected to close in Q1 2026, subject to satisfaction or waiver of customary closing conditions

    80% confidence

  • Sanofi's commercial presence, development capabilities and vision of science-based immunization will amplify opportunities for HEPLISAV-B and innovative pipeline to meet important public health needs

    80% confidence

  • Shingles affects one in three adults during their lifetime

    80% confidence

  • The marketed adult hepatitis B vaccine and shingles vaccine candidate add new options to Sanofi's portfolio and underscore commitment to providing vaccine protection throughout life

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline — Source | Via News | ViaNews Market